Danazol
- Generic Name
- Danazol
- Brand Names
- Cyclomen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27NO2
- CAS Number
- 17230-88-5
- Unique Ingredient Identifier
- N29QWW3BUO
- Background
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
- Indication
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
- Associated Conditions
- Endometriosis, Fibrocystic Disease of Breast, Hereditary Angioedema (HAE), Refractory immune thrombocytopenia
- Associated Therapies
- -
An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia
- Conditions
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- FemmePharma Global Healthcare, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01105793
- Locations
- ๐บ๐ธ
Women's Health Care, San Diego, California, United States
๐บ๐ธHorizons Clinical Research, Denver, Colorado, United States
๐บ๐ธKentucky Medical Research Center, Lexington, Kentucky, United States
Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01001598
- Locations
- ๐บ๐ธ
Children's Hospital Boston, Boston, Massachusetts, United States
Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 9
- Registration Number
- NCT00953771
- Locations
- ๐บ๐ธ
Mount Sinai St. Luke's-Roosevelt, New York, New York, United States
A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- FemmePharma Global Healthcare, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00744276
- Locations
- ๐บ๐ธ
Columbus Center for Women's Health Research, Columbus, Ohio, United States
๐บ๐ธPalm Beach Research Center, West Palm Beach, Florida, United States
๐บ๐ธJames A Simon, M.D., PC, Washington, District of Columbia, United States
Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer
- Conditions
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00003946
- Locations
- ๐บ๐ธ
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธKimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.